AU consumer-credit & healthcare-payments deep dive (for Eva's trading desk)

Requested by: Eva (desk, local-lane) per Young's pairing directive; tracker task-4b5f9f09. Two lanes full-sourced, verified against primary filings (ASX PDFs, RBA, Equifax, ASIC, Block 10-Q). Split honoured: Eva = desk numbers; Tam = public evidence + verdicts.

Summary (3 bullets)

• No distress in AU consumer credit as of Q2-2026. Zip 1H-FY26 net bad debts 1.73% of TTV (inside 1.5–2.0% target, vs 1.56% 1H25), ANZ losses the lowest since FY23, and FY26 guidance upgraded (record cash EBTDA $124.3m, +85.6%, on TTV $8.4bn, +34.1%). BNPL regulation landed (NCC coverage + credit licence from 10 Jun 2025, ASIC RG 281, AFCA extended) — residual dust is enforcement, not regime change.
• The early-warning metric isn't headline arrears — it's late-stage dollar exposure. Equifax Q1-26: BNPL 90+dpd accounts improved to 1.68%, but late-arrears dollar exposure +10% YoY (personal loans +3.1%, hardship counts up). Yellow flag, not red.
• TYR health-TTV is policy-sensitive but LOW-beta. The Nov-2025 bulk-billing incentives ($7.9bn BBIP/BBPIP extension + 12.5% practice payment) flipped >1,000 clinics to full bulk-billing (BB rate 77.6% → 84.1% by Jun-26) and Tyro booked a disclosed ~1-year transitory drag, concentrated in H2-FY26, ~1–2% at group level. Stock rose on FY26 results; health re-acceleration is baked into FY27 guidance.

Key findings

Lane 1 — Consumer credit / BNPL as market signal

1. Zip is now a US proxy, not an AU one: US = 75% of TTV (+44% growth); ANZ leg benign and funding margins tightening to 1.37% (AU ABS).
2. Afterpay/Block: ~1% risk loss on receivables, BNPL GP $242m/quarter, $2.1bn consumer receivables — but no standalone AU loss disclosure anymore; Zip + Equifax are now the entire public AU BNPL signal.
3. RBA FSR Mar-26: mortgage arrears low, severe stress down since mid-2024, offset buffers building; spillover into unsecured matches past-cycle lags.
4. The leading/lagging map: BNPL losses lag the consumption/rate cycle ~12–18 months (last cycle: 2021 GMV boom → FY22-23 loss peak); BNPL GMV/mix leads discretionary retail; late-stage dollar exposure is the earliest public stress metric — watch it, not the headline account rate.
5. EML is not a consumer-credit read: B2B prepaid/forex/employer payouts only. FY26 underlying revenue −6% to A$206.8m with a A$19.7m NDA is idiosyncratic transformation, not credit signal. (Its severance/payout volumes are a coincident labour-churn read — separate angle.)

Market verdict (desk): benign-to-improving on the AU BNPL book; watch Equifax Q2-26 (late-arrears $ trend is the early tell), RBA FSR Oct-26, Zip 3Q FY26 update ~17 Apr / full FY26 20 Aug. Positioning: no signal for stress trades yet; the malign interpretation needs dollar-exposure acceleration two quarters running.

Lane 2 — TYR and the bulk-billing mechanism

1. Transmission mechanism confirmed: bulk-billed consults pay Medicare directly, bypassing the EFTPOS terminal — mode-shift shows up in Tyro's numbers within one quarter (visible in H1-FY26 commentary; partial Core TTV drag concentrated in H2-FY26, growth deceleration ~9pp on health TTV).
2. Exposure quantified: health TTV $7.9bn FY26 (+6.4%) ≈ 17–18% of group TTV $44.3bn; GP/medical anchor, but dental (+19%) and allied (+26%) accelerating, and Tyro Health Online monetises the claim rails regardless of consult mode.
3. Immunisers: dental/allied are bulk-billing-exempt; banking GP (+23%) diversifies; direct Medicare/DVA claim processing via Health Online keeps the health funnel monetised even when terminals see less.
4. TYR guidance stance: drag explicitly called out as partial, transitory, expected to lap; FY27 guidance $240–255m GP at 28.5–30.5% EBITDA margin assumes health re-acceleration.
5. EML vs TYR: EML's healthcare exposure is payout/benefit-card programming (NSW Health salary packaging, insurance claims) — mode-shift doesn't touch its volumes; the Nov-2025 change is a TYR-specific read.

Market verdict (desk): high-signal (you'll see it fast) but low-beta (bounded, already disclosed, expected to lap). The stock's upward response to FY26 results is consistent with a market that's already priced the drag. What actually moves the needle from here: the FY27 health-TTV re-acceleration proof-point, not the FY26 deceleration. If Young's Pulse wants a single metric: track TYR health TTV growth rate YoY per half against the Medicare BB rate per quarter — the divergence timing is the tradeable signal.

Sources

• Zip 1H-FY26 results (ASX PDF, 19 Feb 2026) + FY26 Annual Report (20 Aug 2026) — bad debts, ECL provisions, TTV mix
• Block Q3-25 presentation + 10-Q (Afterpay segment data)
• ASIC RG 281 (8 May 2025), INFO 285 — BNPL under NCC framework
• RBA Financial Stability Review Mar-2026 — household finances, arrears
• Equifax Q1-2026 Credit Trends — BNPL 90+dpd, personal loans, hardship
• EML FY26 coverage — underlying revenue, NDA isolation
• Medicare BBIP/BBPIP Nov-2025 extension + BB rate quarterly series
• Tyro H1-FY26 briefing + FY26 results — health TTV drag/growth commentary, FY27 guidance

Collaboration status

Eva pinged locally (both verdicts). Desk-data merge pending on her side; notes will auto-sync to vault/docs via the mirror cron within 30 minutes.